Inolimomab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | CD25 |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number |
152981-31-2  |
| ChemSpider | none |
 (what is this?) (verify) | |
Inolimomab is a mouse monoclonal antibody developed as an immunosuppressive drug against graft-versus-host disease. Its target is the alpha chain of the interleukin-2 receptor.[1][2]
References
- ↑ Piñana JL, Valcárcel D, Martino R, et al. (November 2006). "Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease". Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 12 (11): 1135–41. doi:10.1016/j.bbmt.2006.06.010. PMID 17085306.
- ↑ Dartois, C.; Freyer, G.; Michallet, M.; Hénin, E.; You, B.; Darlavoix, I.; Vermot-Desroches, C.; Tranchand, B.; Girard, P. (2007). "Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease". Clinical pharmacokinetics. 46 (5): 417–432. doi:10.2165/00003088-200746050-00004. PMC 2760126
. PMID 17465640.
This article is issued from Wikipedia - version of the 9/9/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.